Subscribe
Magazine
Videos
Advertise
About Us
Smart Water Summit
Wastewater Summit
Drinking Water
Smart Water
Asset Management
Water Utility Management
Water Reuse
Global Thought Leaders
Podcast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
WaterWorld Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
6.020
+0.045 (+0.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mind Medicine Mindmed Inc
< Previous
1
2
3
4
5
Next >
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
August 13, 2024
From
Mind Medicine Inc.
Via
Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
August 09, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
August 09, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 06, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
August 06, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
July 29, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
July 17, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
June 28, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 21, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
June 20, 2024
From
Mind Medicine
Via
Business Wire
MindMed to Participate in June Conferences
May 28, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed to Participate at May Investor Conferences
May 09, 2024
From
MindMed
Via
Business Wire
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
May 09, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Reports First Quarter 2024 Financial Results and Business Updates
May 08, 2024
From
MindMed
Via
Business Wire
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
May 04, 2024
From
MindMed
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
May 02, 2024
From
MindMed
Via
Business Wire
MindMed to Present at Upcoming May Medical Conferences
April 25, 2024
From
MindMed
Via
Business Wire
MindMed to Present at Upcoming April Medical Conferences
April 02, 2024
From
Mind Medicine
Via
Business Wire
MindMed Announces Voluntary Delisting from Cboe Canada
April 01, 2024
From
MindMed
Via
Business Wire
The Next Great Biotech Boom Has Arrived
March 19, 2024
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
March 11, 2024
From
MindMed
Via
Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
March 07, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
March 07, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
March 01, 2024
From
MindMed
Via
Business Wire
MindMed Reports 2023 Financial Results and Business Updates
February 28, 2024
From
MindMed
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
February 22, 2024
From
MindMed
Via
Business Wire
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
February 07, 2024
From
MindMed
Via
Business Wire
MindMed Announces Business Update and Anticipated Milestones for 2024
January 08, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
January 24, 2024
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
December 14, 2023
From
Mind Medicine
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.